Clients

OncoSec Medical Inc.

Company Snapshot: OncoSec Medical Inc.

ONCS
Last Change Volume High Low

Company Overview

OncoSec Medical Inc. is a biopharmaceutical company developing its advanced-stage ImmunoPulse immunotherapy to treat solid tumors. OncoSec Medical's core technology leverages a proprietary electroporation platform to enhance the local delivery and uptake of IL-12 and other DNA-based immunocytokines. Clinical studies of ImmunoPulse have demonstrated positive safety and preliminary efficacy in the treatment of various skin cancers, as well as its potential to initiate a systemic immune response without the toxicities associated with other systemic treatments. OncoSec's clinical programs currently include three Phase 2 clinical trials targeting metastatic melanoma, Merkel cell carcinoma and cutaneous T-cell lymphoma. As the company continues to evaluate ImmunoPulse in these indications, it is also investigating additional indications as well as efficacious combination approaches.

Featured Documents

Client News

  1. Jun 12 2017 OncoSec Announces Technology Access Program Agreement with Jounce Therapeutics, Inc.
  2. Jun 8 2017 OncoSec Granted Orphan Drug Designation from the U.S. FDA for the Treatment of Unresectable Metastatic Melanoma
  3. Jun 2 2017 OncoSec to Present at LD Micro Invitational
  4. Jun 1 2017 OncoSec Announces Third Quarter and YTD Results for Fiscal Year 2017